1
Clinical Trials associated with Sulfamonomethoxine/TrimethoprimA Phase 2, Double-blind, Randomized, Active-controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Drug Resistant E. Coli
This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an active acute uncomplicated UTI at baseline.
100 Clinical Results associated with Sulfamonomethoxine/Trimethoprim
100 Translational Medicine associated with Sulfamonomethoxine/Trimethoprim
100 Patents (Medical) associated with Sulfamonomethoxine/Trimethoprim
100 Deals associated with Sulfamonomethoxine/Trimethoprim